Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

NCT00940316 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: panitumumab
DRUG: erlotinib hydrochloride
DRUG: irinotecan hydrochloride

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]